Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Five-year follow-up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE-AMI trial

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • Anthony Mathur
  • Doo Sun Sim
  • Fizzah Choudry
  • Jessry Veerapen
  • Martina Colicchia
  • Tymoteusz Turlejski
  • Mohsin Hussain
  • Stephen Hamshere
  • Didier Locca
  • Roby Rakhit
  • Tom Crake
  • Jens Kastrup
  • Samir Agrawal
  • Daniel A Jones
  • John Martin
Vis graf over relationer

AIMS: The long-term outcomes of the intracoronary delivery of autologous bone marrow-derived cells (BMCs) after acute myocardial infarction are not well established. Following the promising 1 year results of the REGENERATE-AMI trial (despite it not achieving its primary endpoint), this paper presents the analysis of the 5 year clinical outcomes of these acute myocardial infarction patients who were treated with an early intracoronary autologous BMC infusion or placebo.

METHODS AND RESULTS: A 5 year follow-up of major adverse cardiac events (defined as the composite of all-cause death, recurrent myocardial infarction, and all coronary revascularization) and of rehospitalization for heart failure was completed in 85 patients (BMC n = 46 and placebo n = 39). The incidence of major adverse cardiac events was similar between the BMC-treated patients and the placebo group (26.1% vs. 18.0%, P = 0.41). There were no cases of cardiac death in either group, but an increase in non-cardiac death was seen in the BMC group (6.5% vs. 0%, P = 0.11). The rates of recurrent myocardial infarction and repeat revascularization were similar between the two groups. There were no cases of rehospitalization for heart failure in either group.

CONCLUSION: This 5 year follow-up analysis of the REGENERATE-AMI trial did not show an improvement in clinical outcomes for patients treated with cell therapy. This contrasts with the 1 year results which showed improvements in the surrogate outcome measures of ejection fraction and myocardial salvage index.

OriginalsprogEngelsk
TidsskriftESC Heart Failure
Vol/bind9
Udgave nummer2
Sider (fra-til)1152-1159
Antal sider8
ISSN2055-5822
DOI
StatusUdgivet - apr. 2022

Bibliografisk note

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

ID: 79924514